TRACON Pharmaceuticals Stock Forecast for 2023 - 2025 - 2030
Updated on 05/16/2024
TRACON Pharmaceuticals Stock Forecast and Price Target
TRACON Pharmaceuticals's stock price reaches the average target of $30.50 by 2025 as expected recently by notable experts, there would be a potential upside of approximately 1893.46% from the last closing price in May, 2024. This possible increase is based on a high estimate of $55.00 and a low estimate of $6.00. Even if you are not interested in TCON stock, you should still be aware of its competitors.
1893.46% Upside
TRACON Pharmaceuticals Fair Value Forecast for 2023 - 2025 - 2030
TRACON Pharmaceuticals's Price has increased by 100.00% In the last four years, going from $0.00 to $0.00. In the next year, analysts expect Fair Value to reach $1.64 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ABBV Stock Forecast | AbbVie | Outperform |
9
|
$164.35 | Buy/Sell | $178.42 | 9.52% |
| AMGN Stock Forecast | Amgen | Outperform |
4
|
$314.72 | Buy/Sell | $303.65 | 1.68% |
| GILD Stock Forecast | Gilead Sciences Inc | Outperform |
11
|
$67.86 | Buy/Sell | $87.82 | 17.89% |
| ALXN Stock Forecast | Alexion Pharmaceuticals | - |
0
|
$182.50 | Buy/Sell | $177.38 | -100.00% |
| BIIB Stock Forecast | Biogen | Outperform |
10
|
$230.04 | Buy/Sell | $299.62 | 25.41% |
TRACON Pharmaceuticals Revenue Forecast for 2023 - 2025 - 2030
TRACON Pharmaceuticals's Revenue has increased by 3342.86% In the last year, going from $350.00k to $12.05M. In the following year, the 2 analysts surveyed believe that TRACON Pharmaceuticals's Revenue will decrease by 100.00%, reaching $0.00. For the next seven years, the forecast is for Revenue to grow by 2430.79%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMRN Stock Forecast | BioMarin Pharmaceutical | Outperform |
10
|
$76.97 | Buy/Sell | $111.56 | 43.56% |
| INCY Stock Forecast | Incyte | Outperform |
9
|
$56.86 | Buy/Sell | $77.05 | 38.06% |
| VKTX Stock Forecast | Viking Therapeutics | Buy |
5
|
$69.06 | Buy/Sell | $34.00 | 66.52% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BPMC Stock Forecast | Blueprint Medicines | Outperform |
6
|
$106.64 | Buy/Sell | $85.71 | 12.53% |
| ARNA Stock Forecast | Arena Pharmaceuticals | - |
6
|
$99.99 | Buy/Sell | $100.00 | -100.00% |
| IOVA Stock Forecast | Iovance Biotherapeutics | Buy |
4
|
$10.43 | Buy/Sell | $20.42 | 139.69% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CCXI Stock Forecast | ChemoCentryx | - |
8
|
$51.99 | Buy/Sell | $52.00 | -100.00% |
| CBAY Stock Forecast | CymaBay Therapeutics | Hold |
8
|
$32.44 | Buy/Sell | $27.73 | -100.00% |
| ARWR Stock Forecast | Arrowhead Pharmaceuticals | Outperform |
7
|
$25.00 | Buy/Sell | $52.00 | 120.00% |
TRACON Pharmaceuticals EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, TRACON Pharmaceuticals's EBITDA has decreased by 57.56%, from $-16.21M to $-6.88M. Next year, analysts are expecting EBITDA to reach $-12.94M – an increase of 88.07%. Over the next seven years, the forecast is for EBITDA to grow by 356.49%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| DRNA Stock Forecast | Dicerna Pharmaceuticals | - |
7
|
$38.01 | Buy/Sell | $35.06 | -100.00% |
| FOLD Stock Forecast | Amicus Therapeutics | Outperform |
7
|
$9.50 | Buy/Sell | $17.90 | 89.47% |
| CLDX Stock Forecast | Celldex Therapeutics | Buy |
11
|
$39.94 | Buy/Sell | $63.29 | 77.77% |
TRACON Pharmaceuticals EBIT Forecast for 2023 - 2025 - 2030
In the last three years, TRACON Pharmaceuticals's EBIT has fallen from $-16.22M to $-6.90M – a 57.46% decrease. For next year, analysts predict EBIT of $-34.25M, which would mean an increase of 396.38%. By 2030, professionals believe that TRACON Pharmaceuticals's EBIT will decrease by 3222.17%, reaching $215.43M – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ACAD Stock Forecast | ACADIA Pharmaceuticals | Outperform |
6
|
$14.85 | Buy/Sell | $33.78 | 88.55% |
| VCEL Stock Forecast | Vericel | Buy |
8
|
$47.61 | Buy/Sell | $42.58 | 17.62% |
| ADMA Stock Forecast | ADMA Biologics | Buy |
9
|
$9.06 | Buy/Sell | $6.00 | 10.38% |
TRACON Pharmaceuticals EPS Price Prediction Forecast for 2023 - 2025 - 2030
TRACON Pharmaceuticals's EPS has increased by 100.00% In the last four years, going from $-1.87 to $0.00. In the next year, analysts expect EPS to reach $-1.72 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ARDX Stock Forecast | Ardelyx | Buy |
11
|
$7.79 | Buy/Sell | $9.94 | 79.72% |
| AGIO Stock Forecast | Agios Pharmaceuticals | Outperform |
9
|
$35.00 | Buy/Sell | $40.00 | 27.14% |
| DVAX Stock Forecast | Dynavax Technologies | Outperform |
11
|
$11.28 | Buy/Sell | $25.00 | 121.63% |
Site Navigation
.jpg)